BCDA (BioCardia) PB Ratio: (As of Jun. 25, 2026)


BCDA BioCardia Inc BCDA
21 GF Score
Price $1.09
GF Value $0.05
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is BioCardia PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), BioCardia's share price is $1.09. BioCardia's Book Value per Share for the quarter that ended in Mar. 2026 was $-0.10. Hence, BioCardia's PB Ratio of today is .

The historical rank and industry rank for BioCardia's PB Ratio or its related term are showing as below:

During the past 13 years, BioCardia's highest PB Ratio was 67.69. The lowest was 1.20. And the median was 7.83.

BCDA's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.8
* Ranked among companies with meaningful PB Ratio only.

During the past 3 years, the average Book Value Per Share Growth Rate was -71.70% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BioCardia was 63.30% per year. The lowest was -73.00% per year. And the median was -26.65% per year.

Back to Basics: PB Ratio


BioCardia  (NAS:BCDA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


BioCardia PB Ratio Related Terms


BioCardia PB Ratio Historical Data

* Premium members only.

The historical data trend for BioCardia's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCardia PB Ratio Chart

BioCardia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.16 8.57 0.00 11.98 15.06

BioCardia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 5.20 15.06 0.00

BCDA vs BIVI, GOVX, KAPA: PB Ratio Comparison

For the Biotechnology subindustry, BioCardia's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCardia PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCardia's PB Ratio distribution charts can be found below:

* The bar in red indicates where BioCardia's PB Ratio falls into.


BCDA
21GF Score
BioCardia Inc BCDA
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCardia PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

BioCardia's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=1.09/-0.097
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is BioCardia (BCDA) Overvalued in 2026?

Based on GuruFocus' analysis, BioCardia stock appears to be overvalued. The current stock price of $1.09 is trading 2080% above its estimated GF Value™ of $0.05. GuruFocus considers BioCardia to be Significantly Overvalued.

Key valuation signals for BCDA:

  • PB Ratio:
  • GF Value™: $0.05 vs. price of $1.09 (2080% above fair value)
  • GF Score™: 21/100 with 1 warning sign

No single metric tells the full story. See the BCDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCardia Business Description

Address 320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
21GF Score

Get the complete analysis for BCDA

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.09
Price
$0.05
GF Value